Cogstate (ASX:CGS) said that for the fiscal half ended Dec. 31, 2024, it reported total revenue of about AU$23.9 million, an increase of 19% from AU$20.2 million a year earliere, according to a Monday filing with the Australian bourse.
Clinical trials revenue rose 27% to about AU$22.7 million over the same period. Net clinical trials sales contracts executed clocked in at AU$20.3 million, a growth of 86% from the prior corresponding half-year.
It also bought back 1.4 million ordinary shares for a total cost of AU$1.6 million, at an average cost of AU$1.12 per share.
The firm's shares rose almost 5% in recent trading on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.